Literature DB >> 11313243

Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion.

B N Setty1, S Kulkarni, C D Dampier, M J Stuart.   

Abstract

To assess whether fetal hemoglobin (HbF) modulates the adhesion of sickle erythrocytes to endothelium, children with homozygous sickle cell anemia (SS disease) were studied, using this physiologically crucial period to evaluate the relationships between HbF and the major erythrocyte adhesion markers. The mean level of CD36(+) erythrocytes was 2.59% +/- 2.15% (+/- SD, n = 40) with an inverse relationship between CD36 positivity and F cells (R = -0.76, P < .000 00 002). In univariate analyses, significant correlations with various hematologic parameters and age were noted. Multiple regression analyses, however, revealed a relationship solely with F cells. Minimal levels of very late activation antigen-4(+) (VLA4(+)) erythrocytes (0.31% +/- 0.45%, n = 40) with relationships similar to those noted for CD36(+) cells were also observed. The subpopulation of strongly adhesive stress reticulocytes was further assessed, using CD71 as their marker. The mean level of CD71(+) erythrocytes was 5.81% +/- 4.21%, with statistical correlates in univariate and multivariate analyses similar to those discussed above. When adhesion ratios were evaluated, inverse correlations were noted between basal and plasma-induced adhesion and F-cell numbers (R = -0.54, P < .0005; R = -0.53, P < .0006, n = 39). In addition, in analyses where basal or plasma-induced adhesion was the dependent variable and the independent variables included F cells and the various adhesion-related parameters, significant relationships solely with F cells were noted. The results demonstrate that SS patients with higher levels of F cells have concomitant decreases in the numbers of CD36(+), VLA4(+), and CD71(+) erythrocytes and that these findings translate into less adherent erythrocytes. These findings extend knowledge regarding the protective effects of HbF in the pathophysiology of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313243     DOI: 10.1182/blood.v97.9.2568

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

Review 2.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

3.  Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes.

Authors:  B N Yamaja Setty; Suhita Gayen Betal
Journal:  Blood       Date:  2007-10-02       Impact factor: 22.113

4.  Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain.

Authors:  Suhita Gayen Betal; B N Yamaja Setty
Journal:  Transl Res       Date:  2008-09-04       Impact factor: 7.012

Review 5.  Sickle red cell-endothelium interactions.

Authors:  Dhananjay K Kaul; Eileen Finnegan; Gilda A Barabino
Journal:  Microcirculation       Date:  2009-01       Impact factor: 2.628

6.  Heterogeneous red blood cell adhesion and deformability in sickle cell disease.

Authors:  Yunus Alapan; Jane A Little; Umut A Gurkan
Journal:  Sci Rep       Date:  2014-11-24       Impact factor: 4.379

Review 7.  Triggers, inhibitors, mechanisms, and significance of eryptosis: the suicidal erythrocyte death.

Authors:  Elisabeth Lang; Florian Lang
Journal:  Biomed Res Int       Date:  2015-03-04       Impact factor: 3.411

Review 8.  Sickle cell anaemia: progress in pathogenesis and treatment.

Authors:  Samir K Ballas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.

Authors:  Yunus Alapan; Ceonne Kim; Anima Adhikari; Kayla E Gray; Evren Gurkan-Cavusoglu; Jane A Little; Umut A Gurkan
Journal:  Transl Res       Date:  2016-03-19       Impact factor: 7.012

10.  Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Authors:  Robert Molokie; Donald Lavelle; Michel Gowhari; Michael Pacini; Lani Krauz; Johara Hassan; Vinzon Ibanez; Maria A Ruiz; Kwok Peng Ng; Philip Woost; Tomas Radivoyevitch; Daisy Pacelli; Sherry Fada; Matthew Rump; Matthew Hsieh; John F Tisdale; James Jacobberger; Mitch Phelps; James Douglas Engel; Santhosh Saraf; Lewis L Hsu; Victor Gordeuk; Joseph DeSimone; Yogen Saunthararajah
Journal:  PLoS Med       Date:  2017-09-07       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.